

June 5, 2018



Ceapro Announces Results of 2018 Shareholders' Meeting

EDMONTON, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- [Ceapro Inc.](#) (TSX-V:CZO) (“**Ceapro**” or the “**Company**”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its annual general and special meeting of shareholders held on May 29, 2018 as per following results:

Nominee	Votes for	Votes withheld	% of votes cast	
			FOR	WITHELD
Glenn Rourke	14,547,962	366,358	97.54%	2.46%
Gilles Gagnon	14,318,305	596,015	96.00%	4.00%
Donald Oborowsky	14,434,462	479,858	96.78%	3.22%
John Zupancic	14,319,462	594,858	96.01%	3.99%
Dr. Ulrich Kosciessa	14,697,962	216,358	98.55%	1.45%
Dr. William Li	14,697,962	216,358	98.55%	1.45%

All other matters at the Shareholders' meeting, namely the appointment of auditors and the re-approval and ratification of the Company's Stock Option Plan as proposed in the Company's information circular dated April 18, 2018, were also approved by shareholders.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E: jenene@jenenethomascommunications.com

Source: Ceapro Inc.



Source: Ceapro Inc.